Impact of SAfinamide on Depressive Symptoms in Parkinson’s Disease Patients (SADness-PD Study): A Multicenter Retrospective Study

• DOI: 10.3390/brainsci11020232
• Publication Date: 2021-02-14T01:48:38Z
• Authors: Esteban Peña; Carmen Borrué; Marina Mata; Juan Martínez-Cas...; Araceli Alonso-Ca...; Juan Chico; Lydia López-Manza...; Marcos Llanero; Jaime Herreros-Ro...; Alberto Esquivel; Teresa Maycas-Cepeda; Cristina Ruíz-Huete
• Keywords: Depression; Clinical Global Impression; Serotonin Syndrome

Background: We aimed to assess the effects of safinamide on depression, motor symptoms, and serotonin syndrome related its co-administration with antidepressants in patients Parkinson’s disease (PD). Methods: retrospectively analyzed data at 1 3 months follow-up compared baseline. Results: n = 82 (safinamide 50 mg 22, 100 60, 44). First, we found improvement depression (Hamilton Depression Rating Scale: −6 ± 5.10 month −7.27 months, p < 0.0001; Patient Global Impression Improvement 60.3% 69.5% reported some improvement). Second, improved daily life activities symptoms/motor complications (Unified Disease Scale (UPDRS-II): −2.51 6.30 −2.47 6.11 III: −3.58 8.68 −4.03 8.95 IV: −0.61 2.61 −0.8 2.53 0.0001). Third, 7.31% 8.53% developed non-severe adverse events months. Serotonin was not observed treated antidepressants; isolated symptoms were reported. Conclusions: Safinamide could be useful for treating PD; it effective safe even when co-administered antidepressants.